Democratic senator takes Tom Price to task over questionable stock purchases


Rep. Tom Price (R-Ga.) faced intense questioning from Sen. Patty Murray (D-Wash.) on Wednesday over his decision to purchase Innate Immunotherapeutics stock after a conversation with Rep. Chris Collins (R-N.Y.). "Rep. Price, recent press reports about your investments in the Australian biotech company, Innate Immunotherapeutics, raise some curious questions about your judgments, and I want to review the facts," Murray began. "You made the decision to purchase that stock, not a broker, yes or no?"
"That was a decision I made, yes," Price answered.
Murray continued to push in her questioning: "Congressman Chris Collins, who sits on President-elect Trump's transition team, is both an investor and a board member of [Innate Immunotherapeutics]. He was reportedly overheard just last week off the House floor bragging about how he had made people millionaires from a stock tip," she said. "Congressman Price, in our meeting, you informed me you made purchases based on conversations with Rep. Collins, is that correct?"
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Price has denied the accusation, claiming he had spoken to Collins simply about the company in general — but it's certainly not a great moment for the congressman. "[Innate Immunotherapeutics'] drug could benefit from the 21st Century Cures Act, which Mr. Price voted for. The law, signed in December, will speed up the Food and Drug Administration's approval of new medicines," The New York Times reports. "At the very least, Mr. Price exercised abysmal judgment by trading the shares of companies over whose fortunes he exercised so much control."
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Jeva Lange was the executive editor at TheWeek.com. She formerly served as The Week's deputy editor and culture critic. She is also a contributor to Screen Slate, and her writing has appeared in The New York Daily News, The Awl, Vice, and Gothamist, among other publications. Jeva lives in New York City. Follow her on Twitter.
-
Trump said to seek government stake in Intel
Speed Read The president and Intel CEO Lip-Bu Tan reportedly discussed the proposal at a recent meeting
-
US to take 15% cut of AI chip sales to China
Speed Read Nvidia and AMD will pay the Trump administration 15% of their revenue from selling artificial intelligence chips to China
-
NFL gets ESPN stake in deal with Disney
Speed Read The deal gives the NFL a 10% stake in Disney's ESPN sports empire and gives ESPN ownership of NFL Network
-
Samsung to make Tesla chips in $16.5B deal
Speed Read Tesla has signed a deal to get its next-generation chips from Samsung
-
FCC greenlights $8B Paramount-Skydance merger
Speed Read The Federal Communications Commission will allow Paramount to merge with the Hollywood studio Skydance
-
Tesla reports plummeting profits
Speed Read The company may soon face more problems with the expiration of federal electric vehicle tax credits
-
Dollar faces historic slump as stocks hit new high
Speed Read While stocks have recovered post-Trump tariffs, the dollar has weakened more than 10% this year
-
Economists fear US inflation data less reliable
speed read The Labor Department is collecting less data for its consumer price index due to staffing shortages